Ian Eliason

Ian Eliason Email and Phone Number

Venture Capitalist & Advisor @ Zoic Capital
Ian Eliason's Location
United States, United States
Ian Eliason's Contact Details

Ian Eliason work email

Ian Eliason personal email

About Ian Eliason

I've always been curious, trying to cultivate a deeper understanding of the world. That same curiosity has also lead me "off the beaten path" to find keys that unlock simple solutions to big problems.That same mentality led me to co-found Zoic Capital, where my work consists of analysis, diligence, and optimization.Zoic Capital operates as a middleman, pulling in investor capital and deploying it into companies that solve big problems dominantly. In turn, this process allows my team and I to help our portfolio companies and investors:► Develop large scale inclusive IP development strategies► Help connect and codevelop deals with potential strategic acquirersWe are currently the only US-based venture firm focused solely on investing in the seed stage of Medtech, going through a rigorous vetting process with each investment opportunity to ensure that:1. their technological developments represent at least a 10X improvement in the current standard of care2. their technology relies on scientific mechanisms which are fully supported by published literature, independent trials, and personal observation3. in most cases, they have unique hardware and IP coupled with unique software4. the leadership team has the necessary combination of vision and experience to create a transformational company5. they have initial regulatory approval on a short timeline, typically two to four years.Throughout this process, my job is to find the core USP, issues, and areas of improvement for each of our portfolio companies and for each of the opportunities that come across our table. Then, ultimately determine how we can implement tactical insights, providing value to the company, and, as a result, our investors.If you want to learn more about Zoic, the types of companies we invest in, or if you’d like to exchange good reads and travel ideas, send me an email: ian@zoiccapital.comIf you know of an interesting deal for Zoic to look at, feel free to get in touch with my team here: deals@zoiccapital.com

Ian Eliason's Current Company Details
Zoic Capital

Zoic Capital

View
Venture Capitalist & Advisor
Ian Eliason Work Experience Details
  • Zoic Capital
    Partner & Co-Founder
    Zoic Capital Oct 2014 - Present
    Seattle, Washington, Us
    Zoic is an IP centric life sciences venture fund. We are actively seeking to invest in early stage companies that:1. Have technology with a primary medical application; any technology except for those considered a pharmaceutical by the FDA.2. The technology represents 10x magnitudes of improvement over current standard of care, or has no equivalent.3. We prefer unique hardware and IP coupled with unique software.4. Technology has the potential to be used as a platform for multiple medical, and possibly non-medical, applications.5. Currently raising in the seed round, or before any regulatory approval with some feasibility work done.Specific examples including: molecular diagnostics, particularly for direct to consumer use, noninvasive imaging, noninvasive diagnostics and therapies for mental health, surgical tools, synthetic cardiovascular components.
  • Hdt Bio
    Investor & Advisor
    Hdt Bio Jul 2020 - Present
    Seattle, Washington, Us
    Investor in HDT Bio. A biopharmaceutical company addressing the urgent need for cost-effective vaccines to prevent infectious diseases across the globe.HDT Bio, was formed by a group of experienced entrepreneurs with decades of success in biopharmaceutical research and vaccine development around the world.
  • Trio Labs, Inc.
    Investor & Advisor
    Trio Labs, Inc. May 2024 - Present
    Morrisville, North Carolina, Us
    Investor in Trio Labs. Trio Labs' mission is to improve lives by enabling the next generation of medical devices. Trio fabricates precision metal parts with unmatched fine resolution that scale seamlessly from prototyping though high volume manufacturing. The Resin Infused Powder Lithography (RIPL) process reduces costs and manufacturing times for existing products, and enables wholly new solutions in a wide range of medical device markets such as high precision surgical tools, interventional devices, miniaturized infusion pumps, microneedle arrays, drug delivery devices, and more.
  • Chromatan, Inc
    Investor & Advisor
    Chromatan, Inc Jan 2023 - Present
    Ambler, Pa, Us
    Investor in Chromatan. The future of single-use, column-free purification.Purification of proteins and vaccines is vital to biotechnology. Innovation in this industry has lagged, leading to manufacturing bottlenecks, especially in antibody production. ChromaTan has developed Continuous Countercurrent Tangential Chromatography (CCTC) - a new column-free and single-use process that provides a cost saving alternative to column chromatography.ChromaTan's proprietary Countercurrent Tangential Chromatography technology uses an innovative membrane solution to provide the same high level of purification afforded by conventional column designs, with continous output and up to 80% less resin consumption.
  • Probius
    Investor & Advisor
    Probius Dec 2020 - Present
    Fremont, California, Us
    Investor in Probius. Bridging biology and AI, to improve human health. Empowering the future of life science research.
  • Ods Medical Inc
    Board Member
    Ods Medical Inc Nov 2020 - Present
    Montreal, Ca
  • Ods Medical Inc
    Investor & Advisor
    Ods Medical Inc May 2017 - Present
    Montreal, Ca
    Investor in Reveal Surgical/ODS Medical.
  • Ods Medical Inc
    Board Observer
    Ods Medical Inc Jan 2017 - Nov 2020
    Montreal, Ca
    ODS Medical Inc. is a medical device company that seeks to commercialize our exclusive Raman spectroscopy system for real-time detection of tissue abnormalities through the development, manufacture and sales of products for a range of clinical settings.
  • Optina Diagnostics
    Investor & Advisor
    Optina Diagnostics Jun 2018 - Present
    Montréal, Qc, Ca
    Investor in Optina Diagnostics. Optina aims to transform memory loss detection and understanding through a simple eye exam offered in near-patient clinicsOptina at the forefront of innovation To deliver new insights on the most complex and least understood organ, the brain.Alzheimer’s disease is a leading cause of disability and dependency in later life. This condition remains complex and difficult to assess, even by experts.
  • Biorosa Technologies
    Investor & Advisor
    Biorosa Technologies Dec 2020 - Present
    Boston, Ma, Us
    Investor in BioRosa. The Future of Autism Spectrum Disorder DetectionBioROSA’s Test Provides a New Way to Detect ASDBioROSA is developing a highly accurate blood test that will detect ASD in children as young as 18 months.Early Intervention FollowsA positive BioROSA test can allow for early intervention services to begin. Early intervention has been shown to improve language, social skills, and IQ for many children with ASD2.The BioROSA test uses a small amount of blood taken from a standard blood draw. They measure a set of blood biomarkers that are predictors of ASD. Computer algorithms are applied to analyze data and provide a risk score for ASD.
  • Innovein
    Investor & Advisor
    Innovein May 2018 - Present
    San Carlos, California, Us
    Investor in InnoVein. InnoVein, a Y Combinator and venture backed medical device company, is developing a first-of-its-kind valve replacement to offer patients their first definitive cure. Its novel award-winning technology is predicated on decades of cardiac and arterial approaches.In aggregate, the InnoVein founding team has invented and brought over 15 medical technologies to market, with leading products selling over $3B.
  • Juno Diagnostics
    Investor & Advisor
    Juno Diagnostics Mar 2018 - Present
    San Diego, Ca, Us
    Investor in Juno Diagnostics. Juno Diagnostics has developed the next generation of non-invasive prenatal tests so that all women can access a higher standard of care.The company founders worked together to pioneer the development and commercialization of the first cell-free DNA-based non-invasive prenatal screen (NIPS) in the United States, trusted by doctors for millions of pregnancies each year.

Ian Eliason Skills

Venture Capital Start Ups Leadership Business Development Strategy Valuation Due Diligence Biotechnology Analysis Investments Risk Management New Business Development Financial Modeling Web Design Strategic Planning Business Strategy

Ian Eliason Education Details

  • University Of Minnesota
    University Of Minnesota
    Communications

Frequently Asked Questions about Ian Eliason

What company does Ian Eliason work for?

Ian Eliason works for Zoic Capital

What is Ian Eliason's role at the current company?

Ian Eliason's current role is Venture Capitalist & Advisor.

What is Ian Eliason's email address?

Ian Eliason's email address is ie****@****ail.com

What schools did Ian Eliason attend?

Ian Eliason attended University Of Minnesota.

What are some of Ian Eliason's interests?

Ian Eliason has interest in Mobile, Health Care, Scuba Diving, Material Sciences, Health, Genomics, Web Design, Clean Technology, Environment, Science And Technology.

What skills is Ian Eliason known for?

Ian Eliason has skills like Venture Capital, Start Ups, Leadership, Business Development, Strategy, Valuation, Due Diligence, Biotechnology, Analysis, Investments, Risk Management, New Business Development.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.